Focusfreda held its 2026 annual work meeting
On January 23, Focusfreda convened its 2026 annual work conference to thoroughly study and implement the directives from the Group's 2026 annual work conference, systematically review the 2025 business performance, and comprehensively outline the 2026 work objectives. Zheng Deqiang, a member of the Freda Party Committee, Vice President, and Chairman of Focusfreda, attended the meeting and delivered a concluding speech.
The meeting conveyed and studied the key points from two speeches: Wang Xuchao, Party Secretary and Chairman of Lushang Group, delivered at the Group's 2026 Annual Work Conference; and Zhang Daizhou, Assistant General Manager of Lushang Group and Party Secretary of Freda, presented a speech titled' Innovation for Quality, Transformation for Strength: Striving to Open a New Chapter of High-Quality Development for Freda'.
The Group's annual work conference emphasized that the raw materials sector must adopt a global strategy and advance toward the high-end of the industrial chain by steadfastly implementing the transformation and upgrading strategy of "pharmaceutical-grade, internationalization, and high added value." As a key enterprise in the Group's raw materials sector, Focusfreda will earnestly fulfill its mission as a "pioneer" and "main force," fully implementing all the Group's decisions and deployments.
During the meeting, department heads reported on the achievements and highlights of 2025 work, current shortcomings and improvement measures, as well as plans for the next steps. The respective division leaders provided comments based on the actual business operations of each sector, analyzed the trends in business development, and made specific arrangements for the work in 2026.
In his speech, Zheng Deqiang commended Focusfreda's achievements in 2025 while highlighting areas requiring further development. He emphasized that the core mission of "solidifying hyaluronic acid's leading edge" under Freda's "1234" high-quality innovation strategy should guide all 2026 initiatives. First, maintain unwavering confidence and strengthen strategic positioning to solidify hyaluronic acid leadership. Second, build a cohesive team committed to pragmatic execution, enhancing delivery capacity, responsiveness, and efficiency to tackle market competition. Third, steadfastly transition to pharmaceutical-grade standards by developing specialized R&D and production teams for premium, high-value pharmaceutical products. Fourth, accelerate technology commercialization through internal R&D and external collaborations, aiming for major breakthroughs in 2026. Fifth, optimize cost-effective operations by piloting new production systems and implementing incentive mechanisms for resource efficiency. Sixth, prioritize key projects with digital transformation and operational upgrades. Seventh, reinforce Focusfreda's role in the raw material sector and establish comprehensive coordination with group divisions. Eighth, uphold bottom-line thinking by strictly adhering to state-owned enterprise audit and compliance standards, prioritizing safety and environmental protection while balancing development and security.
Over 30 participants attended the meeting, including members of Focusfreda's leadership team, department heads, and responsible personnel.
CONTACT US
Tel：+86-0537-3195566
E-mail：sales@focuschem.com
Add：Economic Development Zone, High-speed Railway New District, Qufu City, Jining City, Shandong Province, China
Copyright © 2022 Shandong Focusfreda Biotech Co., Ltd. 鲁ICP备2021008509号-2 Powerby : 300.cn jinan SEO